### Who we are

- A leading global integrated bancassurer
- Presence in 9 markets (4 in Asia¹)
- Serving customers across retail, wealth, corporate/SME and private bank
- Offering products that meet protection, health, savings, investment, retirement and legacy planning needs
- Complementary products from **strategic partners** in **30 markets**
- Key pillar of our Asian Wealth strategy

Our purpose	Opening up a world of opportunity			
HSBC Life mission	To offer "a promise of Health, Protection and Prosperity" to our customers			
Our strategy	Focus on our strengths	Digitise at scale	Energise for growth	Transition to net zero


# 1H22 business highlights

- Completed the acquisition of **AXA Singapore** for \$0.5bn
- Completed the acquisition of remaining 50% equity interest in HSBC Life China
- Renewed our exclusive distribution agreement with Allianz for life and non-life insurance in six key Asia markets<sup>2</sup> for 15 years
- Market leadership in HK<sup>3</sup>, #1 ranked with a market share of 23.6% for 1H22
- Expanded Pinnacle Venture to 6 major cities<sup>4</sup> in mainland China with over 1,000 Personal Wealth Planners and c.360k registered users of the HSBC River app
- Over c.115k member registrations<sup>5</sup> on our **digital health and wellness platforms** in Hong Kong

1


# 1H22 key financials

Financial results for the Insurance business are prepared on the current IFRS 4 basis and, as such, do not reflect any potential impacts of IFRS 17 'Insurance Contracts', which is effective from 1 January 2023




Denotes an alternative performance measure


# 1H22 manufacturing adjusted revenue by region, \$m



# 9 Manufacturing markets + Bermuda Captive



# 1H22 distribution income<sup>8</sup> by region, \$m



Distribution markets

# 22 markets distributing only Partners' products

30


Strategic partnerships

Allianz	Aviva	AXA	
QBE	MetLife	Zurich	


# Financial highlights

Financial results for the Insurance business are prepared on the current IFRS 4 basis and, as such, do not reflect any potential impacts of IFRS 17 'Insurance Contracts', which is effective from 1 January 2023


### Adjusted profit before tax, \$m



Reported Embedded Value<sup>5,6</sup>, \$bn



# Adjusted ANP and VNB5, \$m



### Insurance manufacturing sensitivities

1H22 sensitivity to market risk factors	Effect on profit after tax, \$m	
+100 basis point parallel shift in yield curves	(136)	
-100 basis point parallel shift in yield curves	(47)	
10% increase in equity prices	373	
10% decrease in equity prices	(388)	

# 1H22 VNB by region



### Adjusted income statement, \$m

	1H22	1H21	2H21
Revenue	1,060	1,509	1,190
Of which: NII	1,254	1,205	1,244
Of which: market impacts	(680)	391	97
Of which: Funds on deposit	294	_	_
ECL	(8)	(19)	(1)
Operating expenses	(416)	(271)	(332)
Share of profit in associates and JVs	4	7	10
Profit before tax	640	1,226	867
Memo: distribution income <sup>8</sup>	470	430	378

#### Important notice

The information, statements and opinions set out in this presentation and accompanying discussion ("this Presentation") are for informational and reference purposes only and do not constitute a public offer for the purposes of any applicable law or an offer to sell or solicitation of any offer to purchase any securities or other financial instruments or any advice or recommendation in respect of such securities or other financial instruments.

This Presentation, which does not purport to be comprehensive nor render any form of legal, tax, investment, accounting, financial or other advice, has been provided by HSBC Holdings plc (together with its consolidated subsidiaries, the "Group") and has not been independently verified by any person. You should consult your own advisers as to legal, tax investment, accounting, financial or other related matters concerning any investment in any securities. No responsibility, liability or obligation (whether in tort, contract or otherwise) is accepted by the Group or any member of the Group or any of their affiliates or any of its or their officers, employees, agents or advisers (each an "Identified Person") as to or in relation to this Presentation (including the accuracy, completeness or sufficiency thereof) or any other written or oral information made available or any errors contained therein or omissions therefrom, and any such liability is expressly disclaimed.

No representations or warranties, express or implied, are given by any Identified Person as to, and no reliance should be placed on, the accuracy or completeness of any information contained in this Presentation, any other written or oral information provided in connection therewith or any data which such information generates. No Identified Person undertakes, or is under any obligation, to provide the recipient with access to any additional information, to update, revise or supplement this Presentation or any additional information or to remedy any inaccuracies in or omissions from this Presentation. Past performance is not necessarily indicative of future results. Differences between past performance and actual results may be material and adverse.

#### **Forward-looking statements**

This Presentation may contain projections, estimates, forecasts, targets, opinions, prospects, results, returns and forward-looking statements with respect to the financial condition, results of operations, capital position, strategy and business of the Group which can be identified by the use of forward-looking terminology such as "may", "will", "should", "expect", "anticipate", "project", "plan", "estimate", "seek", "intend", "target" or "believe" or the negatives thereof or other variations thereon or comparable terminology (together, "forward-looking statements"), including the strategic priorities and any financial, investment and capital targets and any ESG related targets, commitments and ambitions described herein. Any such forward-looking statements are not a reliable indicator of future performance, as they may involve significant stated or implied assumptions and subjective judgements which may or may not prove to be correct. There can be no assurance that any of the matters set out in forward-looking statements are attainable, will actually occur or will be realised or are complete or accurate. The assumptions and judgments may prove to be incorrect and involve known and unknown risks, uncertainties, contingencies and other important factors, many of which are outside the control of the Group. Actual achievements, results, performance or other future events or conditions may differ materially from those stated, implied and/or reflected in any forward-looking statements due to a variety of risks, uncertainties and other factors (including without limitation those which are referable to general market conditions, regulatory changes, the impact of the Covid-19 outbreak or as a result of data limitations and changes in applicable methodologies in relation to ESG related matters). Any such forward-looking statements are based on the beliefs, expectations and opinions of the Group at the date the statements are made, and the Group does not assume, and hereby disclaims, any obligation or duty to update, revise or supplement them if circumstances or management's beliefs, expectations or opinions should change. For these reasons, recipients should not place reliance on, and are cautioned about relying on, any forward-looking statements. No representations or warranties, expressed or implied, are given by or on behalf of the Group as to the achievement or reasonableness of any projections, estimates, forecasts, targets, prospects or returns contained herein.

Additional detailed information concerning important factors that could cause actual results to differ materially from this Presentation is available in our Annual Report and Accounts for the fiscal year ended 31 December 2021 filed with the Securities and Exchange Commission (the "SEC") on Form 20-F on 23 February 2022 (the "2021" Form 20-F"), our 1Q 2022 Earnings Release furnished to the SEC on Form 6-K on 26 April 2022 (the "1Q 2022 Earnings Release"), as well as our Interim Financial Report for the six months ended 30 June 2022 furnished to the SEC on Form 6-K on 1 August 2022 (the "2022 Interim Report"), available at <a href="https://www.hsbc.com">www.hsbc.com</a>.

#### **Alternative Performance Measures**

This Presentation contains non-IFRS measures used by management internally that constitute alternative performance measures under European Securities and Markets Authority guidance and non-GAAP financial measures defined in and presented in accordance with SEC rules and regulations ("Alternative Performance Measures"). The primary Alternative Performance Measures we use are presented on an "adjusted performance" basis which is computed by adjusting reported results for the period-on-period effects of foreign currency translation differences and significant items which distort period-on-period comparisons. Significant items are those items which management and investors would ordinarily identify and consider separately when assessing performance in order to better understand the underlying trends in the business.

Reconciliations between Alternative Performance Measures and the most directly comparable measures under IFRS are provided in our 2021 Form 20-F, which is available at www.hsbc.com.

Information in this Presentation was prepared as at 4 October 2022, unless otherwise specified.

### Footnotes:

- 1. Manufacturing markets include Hong Kong, China, Singapore, India, France, UK, Malta, Mexico and Argentina
- 2. China, Taiwan, Malaysia, Indonesia, Philippines and Sri Lanka
- 3. Hong Kong Insurance Authority. Market shares and ranking based on ANP, HSBC Life HK and Hang Seng Insurance combined.
- 4. Expanded to Foshan in May 2022, other presence including Shanghai, Guangzhou, Hangzhou, Shenzhen and Beijing
- 5. Metric excludes Canara HSBC OBC Life Insurance ("CHOICe"), 26% owned Indian associate
- 6. Embedded value is measured as the total IFRS equity of Insurance manufacturing operations.
- 7. India is a 26%-owned associate
- 8. Commission income for selling HSBC manufactured insurance products and insurance products manufactured by third parties
- ). Present value of long-term in-force insurance contracts and investment contracts with discretionary participation features

#### Glossarv

ANP	Annualised new business premiums	
BAU revenue	Manufacturing revenue before market impacts	
ECL	Expected credit losses	
Distribution revenue	ion revenue Commission income for selling HSBC manufactured insurance products and insurance products manufacture by third parties	
VNB	Value of new business written	

# **Key contacts**

### London

### Richard O'Connor

Global Head of Investor Relations <u>richard.j.oconnor@hsbc.com</u> +44 (0) 20 7991 6590

### **Neil Sankoff**

Head of Equity and ESG Investor Relations neil.sankoff@hsbc.com +44 (0) 20 7991 5072

### **Tim Fradin**

Head of Analysts <u>tim.fradin@hsbc.com</u> +44 (0) 20 7992 4834

# **Hong Kong**

### **Mark Phin**

Head of Investor Relations, Asia-Pacific mark.j.phin@hsbc.com +852 2822 4908

### **Laurence Chan**

Senior Investor Relations Manager, Asia laurencechchan@hsbc.com +852 2288 5513